Acting On Ester Bond (3.1) Patents (Class 435/196)
  • Patent number: 10987410
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 27, 2021
    Assignee: Synthetic Biologics, Inc.
    Inventors: Vincent Wacher, J. Blair West, Michael Kaleko, Christian Furlan Freguia
  • Patent number: 10889807
    Abstract: The present disclosure describes a variant polypeptide having lipolytic activity, wherein the variant has an amino acid sequence which, when aligned with the amino acid sequence as set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue at a position corresponding to any of the positions 113, 122, 138, 141, 179, 282, 284, 286, 295, said positions being defined with reference to SEQ ID NO: 2, and wherein said variant has at least 70% identity with the mature polypeptide having lipolytic activity as set out in SEQ ID NO: 2. Such a variant polypeptide may be used in the preparation of a baked product.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 12, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Rene Marcel De Jong, Chantal Christis, Neil Carr
  • Patent number: 10870839
    Abstract: The present invention provides lipolytic enzyme variants. Specifically, the present invention provides lipolytic enzyme variants having two, three, or more modifications as compared to a parent lipolytic enzyme and having at least one improved property. In addition, the present invention provides compositions comprising a lipolytic enzyme variant of the invention. The present invention also provides methods of cleaning using compositions comprising a lipolytic enzyme variant of the invention.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: December 22, 2020
    Assignee: DANISCO US INC
    Inventors: Thomas P. Graycar, Ayrookaran J. Poulose, David A. Estell
  • Patent number: 10858637
    Abstract: The present invention relates to isolated polypeptides with lipase activity. The invention also relates to polynucleotides encoding the polypeptides; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; compositions comprising the polynucleotides and methods of using the polypeptides or the compositions.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: December 8, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Kenneth Jensen, Maria Louise Leth, Anna Verena Reiser, Robert Piotr Olinski, Preben Nielsen, Lone Baunsgaard
  • Patent number: 10858640
    Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 8, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Yuri Koshimura, Miroslav Matev, Hiroyuki Sonoda
  • Patent number: 10801062
    Abstract: The present invention provides methods and systems for sequencing long nucleic acid fragments. In one aspect of the invention, methods, systems and reagent kits are provided for sequencing nucleic acid target sequences. Some embodiments of the methods, systems and reagent kits are particularly suitable for sequencing a large number of fragments, particularly long fragments.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: October 13, 2020
    Assignee: Centrillion Technology Holdings Corporation
    Inventors: Wei Zhou, Rui Mei, Filip Crnogorac, Guochun Liao, Julian Lucas
  • Patent number: 10760037
    Abstract: The present invention relates to a composition comprising: (a) a source of sulfite; and (b) a lipase variant of a parent lipase, wherein said variant has improved stability towards sulfite as compared to the parent lipase.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 1, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Marco Malten, Thomas Agersten Poulsen, Lise Munch Mikkelsen, Dorte Marie Koefoed Klitgaard, Vibeke Skovgaard Nielsen, Katarina Larson
  • Patent number: 10758595
    Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 1, 2020
    Assignee: Precision BioSciences, Inc.
    Inventors: Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • Patent number: 10738305
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: August 11, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Matthew Hebden Porteus
  • Patent number: 10697015
    Abstract: The present invention relates to methods of genotyping for selecting an animal with a desired trait such as the level monounsaturated fats in muscle tissue, the types and/or ratio of different monounsaturated fats in muscle tissue, marbling, carcass weight, meat quality, speed of finishing, feedlot efficiency and/or consumer preference. In particular the invention relates to methods of selecting an animal with a desired trait by analysing the M-RIP, NT5M and/or TCAP genes for one or more polymorphisms.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 30, 2020
    Assignee: CY O'CONNOR ERADE VILLAGE FOUNDATION
    Inventors: Roger Letts Dawkins, John Anthony Millman, Joseph Frederick Williamson, Patrick Robert Carnegie
  • Patent number: 10689631
    Abstract: Unnatural, mutated thioesterases having an amino acid sequence that is at least 80% identical to SEQ ID NO:1 and having substitutions at one or more of amino acid positions I107, R108, L109, S122, M141, E142, Y145, and L146, gene constructs encoding and configured to express the mutated thioesterases in a transformed host cell, and host cells transformed to contain the gene constructs.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: June 23, 2020
    Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION, THE PENN STATE RESEARCH FOUNDATION
    Inventors: Brian F. Pfleger, Nestor Jose Hernandez-Lozada, Costas Maranas, Matthew Grisewood
  • Patent number: 10683542
    Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 16, 2020
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Zachary Zwirko, Yu Zheng, Mirna Jarosz, Caifu Chen, Joseph Walder
  • Patent number: 10675302
    Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 9, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Fyodor Urnov
  • Patent number: 10648001
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 12, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Patent number: 10603363
    Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 31, 2020
    Assignee: Precision BioSciences, Inc.
    Inventors: Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • Patent number: 10590479
    Abstract: A method for sequencing a nucleic acid is provided. In certain embodiments the method comprises obtaining a duplex comprising a nucleic acid and a primer, wherein the primer has a nuclease resistant 3? end, combining the duplex with a chain terminator nucleotide and a proof-reading polymerase to produce a reaction in which the polymerase idles on the added chain terminator nucleotide, identifying the chain terminator nucleotide added to the end of the primer; and adding a nuclease-resistant nucleotide to the end of the primer after the polymerase has idled on and removed the added chain terminator nucleotide, thereby producing a duplex comprising the template and an extended primer that has a nuclease resistant 3? end.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: March 17, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Brian Jon Peter, Joel Myerson
  • Patent number: 10584320
    Abstract: The present invention relates to novel esterase, more particularly to esterase variants having improved thermostability compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: March 10, 2020
    Assignee: CARBIOS
    Inventors: Christopher Topham, Helene Texier, Vincent Tournier, Marie-Laure Desrousseaux, Sophie Duquesne, Isabelle Andre, Sophie Barbe, Alain Marty
  • Patent number: 10465197
    Abstract: The present invention is an inducible coexpression system, capable of controlled induction of expression of each gene product.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: November 5, 2019
    Assignee: AbiSci, LLC
    Inventors: Sean McClain, Mark Valasek
  • Patent number: 10329546
    Abstract: The present invention provides lipolytic enzyme variants. Specifically, the present invention provides lipolytic enzyme variants having two, three, or more modifications as compared to a parent lipolytic enzyme and having at least one improved property. In addition, the present invention provides compositions comprising a lipolytic enzyme variant of the invention. The present invention also provides methods of cleaning using compositions comprising a lipolytic enzyme variant of the invention.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 25, 2019
    Assignee: DANISCO US INC
    Inventors: Thomas P. Graycar, Ayrookaran J. Poulose, David A. Estell
  • Patent number: 10238904
    Abstract: Disclosed herein are non-wild-type organophosphorus acid anhydrolases having two site mutations, methods of production, and methods of use to effectively degrade toxic chemicals such as ((RS)-Propan-2-yl methylphosphonofluoridate) (Sarin) and other organophosphorus compounds.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: March 26, 2019
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Mark A Guelta, Melissa M. Dixon, Steven P Harvey
  • Patent number: 10227622
    Abstract: The present invention provides for a genetically modified host cell comprising a 2-pyrrolidone synthase, or an enzymatically active fragment thereof, heterologous to the host cell.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: March 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Jingwei Zhang, Jay D. Keasling
  • Patent number: 10208319
    Abstract: Disclosed herein are methods, compositions, and kits for high efficiency, site-specific genomic editing of cells for treating or preventing genetic blood disorders.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 19, 2019
    Assignees: President and Fellows of Harvard College, The Children's Medical Center Corporation
    Inventors: Kiran Musunuru, Chad A. Cowan, Derrick J. Rossi
  • Patent number: 10167489
    Abstract: Methods and compositions for the production of dielectric fluids from lipids produced by microorganisms are provided, including oil-bearing microorganisms and methods of low cost cultivation of such microorganisms. Microalgal cells containing exogenous genes encoding, for example, a sucrose transporter, a sucrose invertase, a fructokinase, a polysaccharide-degrading enzyme, a lipid pathway modification enzyme, a fatty acyl-ACP thioesterase, a desaturase, a fatty acyl-CoA/aldehyde reductase, and/or an acyl carrier protein are useful in manufacturing dielectric fluids.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 1, 2019
    Assignee: Corbion Biotech, Inc.
    Inventors: Scott Franklin, Walter Rakitsky, George Rudenko, Xinhua Zhao, Felipe Arana Rodriguez, Wenhua Lu, Janice Wee
  • Patent number: 10150985
    Abstract: Provided are methods of depleting a target nucleic acid from an initial collection of nucleic acids. Aspects of the methods include contacting the initial collection with a nucleic acid guided nuclease specific for the target nucleic acid in a manner sufficient to deplete the target nucleic acid from the initial collection. Depending on a given application, depletion of a target nucleic acid may vary, e.g., where depleting may include cleaving a target nucleic acid in, or selectively separating a target nucleic acid from, the initial collection of nucleic acids. Also provided are compositions and kits for practicing embodiments of the methods.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: December 11, 2018
    Assignee: Takara Bio USA, Inc.
    Inventors: Andrew Alan Farmer, Craig Betts, Nathalie Bolduc
  • Patent number: 10066219
    Abstract: Disclosed are nucleotide sequences encoding thioesterase enzymes, methods for their production, their use in methods to form thioesters, and their use in methods of screening for other wild type bacteria capable of producing said thioesterase enzymes. Also disclosed are compositions comprising thioesters produced by the methods disclosed herein.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: September 4, 2018
    Assignees: Givaudan SA, Utah State University, Wisconsin Alumni Research Foundation
    Inventors: Tarun Bhowmik, Jeff Broadbent, Dennis Welker, James Steele, Mateo Budinich
  • Patent number: 10066027
    Abstract: Disclosed herein is a protein purification system and methods of using the system. In particular, disclosed is a split intein comprising an N-terminal intein segment, which can be immobilized, and a C-terminal intein segment, which has the property of being self-cleaving, and which can be attached to a protein of interest. Through the self-cleaving mechanism of the intein, the protein of interest can be purified.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 4, 2018
    Assignee: Ohio State Innovation Foundation
    Inventors: David Webster Wood, Changhua Shi
  • Patent number: 10011822
    Abstract: A phytase having improved thermostability is disclosed. The phytase has a modified amino acid sequence of SEQ ID NO: 2, wherein the modification is one of mutations A to D. The mutation A is to substitute amino acids at positions 143 and 262 with cysteine, the mutation B is to substitute amino acids at positions 259 and 312 with cysteine, the mutation C is to substitute amino acids at positions 205 and 257 with cysteine, and the mutation D is to substitute amino acids at positions 264 and 309 with cysteine.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: July 3, 2018
    Assignee: DONGGUAN APAC BIOTECHNOLOGY CO., LTD.
    Inventors: Tzu-Hui Wu, Ya-Shan Cheng, Hui-Lin Lai, Cheng-Yen Lin, Tsung-Yu Ko, Jian-Wen Huang, Chun-Chi Chen, Rey-Ting Guo
  • Patent number: 9976130
    Abstract: This invention is directed toward a non-wild-type organophosphorus acid anhydrolase enzyme having two site mutations, method of production, and method of use to more effectively degrade toxic organophosphorus compounds and, in particular, toxic chemical GD (3,3-Dimethylbutan-2-ylmethylphosphonofluoridate), than the wild type organophosphorus acid anhydrolase.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: May 22, 2018
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Mark A Guelta, Melissa M. Dixon, Steven P. Harvey
  • Patent number: 9963708
    Abstract: A recombinant vector enables independent expression of a foreign gene without interfering with a biological circuit of a host cell. A gene encoding a guanylyl cyclase, a gene encoding cGMP receptor protein, and a regulatory nucleotide sequence to which cGMP receptor protein binds, which are derived from a microorganism, are recombined in at least one plasmid. Using the recombinant vector, a foreign gene may be independently expressed without interfering with a biological circuit of a host cell.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 8, 2018
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun Joong Kim, Eun Bin Lee, Sung Hwan You
  • Patent number: 9963715
    Abstract: Disclosed herein are nucleases and methods of using these nucleases for alteration of a globin gene and generation of cells.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: May 8, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Patent number: 9909109
    Abstract: The present invention relates to isolated lipase variants, comprising a substitution at one or more positions corresponding to positions I86D,E,N,Q, E87C, I90D,E,Q, and N92D,E,Q of the mature polypeptide of SEQ ID NO: 2, wherein the variant has lipase activity. In some embodiments the present invention relates to isolated polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; methods of producing the variants; and compositions comprising the variants. The present invention also relates to methods of obtaining lipase variants; methods of cleaning; and use of lipase variants for cleaning.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: March 6, 2018
    Assignee: NOVOZYMES A/S
    Inventors: Jakob Skjold-Joergensen, Jesper Vind, Allan Svendsen
  • Patent number: 9809787
    Abstract: The present invention relates a method of obtaining a detergent composition comprising introducing (a) a lipase variant of a parent lipase which variant has at least 60% sequence identity with SEQ ID NO: 2, a substitution at a position corresponding to D254 of the mature polypeptide of SEQ ID NO: 2 and has lipase activity and (b) an anionic surfactant, wherein said composition has increased stability in comparison with a corresponding composition comprising the parent lipase.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: November 7, 2017
    Assignee: NOVOZYMES A/S
    Inventors: Jesper Vind, Lise Munch Mikkelsen, Marco Malten, Allan Svendsen, Kim Borch
  • Patent number: 9790503
    Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: October 17, 2017
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Qi Zeng
  • Patent number: 9771566
    Abstract: The present invention relates to organophosphorous hydrolase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: September 26, 2017
    Assignee: Novozymes A/S
    Inventors: Bjarne G. Hansen, Lars Kobberoe Skov, Leonardo De Maria, Julie Bille Rannes
  • Patent number: 9713634
    Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 25, 2017
    Assignee: Shire Pharmaceuticals Ireland Limited
    Inventor: Stefan Nilsson
  • Patent number: 9631185
    Abstract: Fusion-proteins containing an enzyme, preferably a feed or food enzyme, coupled to a gut surface-binding domain are presented. The fusion-proteins can be used to promote feed utilization in animals. In a particular example, a Fusion enzyme according to the invention comprising a gut-surface-binding polypeptide segment linked to a phytase show an increased resident time in the gut, which leads to an increased amount of time given to the enzyme to catalyse the corresponding reaction which finally leads to improved feed utilisation.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: April 25, 2017
    Assignee: NOVOZYMES A/S
    Inventors: Ghislain Schyns, Stephane Duval, Aurelie Brelin
  • Patent number: 9605245
    Abstract: The present invention relates to variant phytase enzymes and their use thereof.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 28, 2017
    Assignee: Fornia BioSoultions, Inc.
    Inventors: Goutami Banerjee, Khin Oo, Xiyun Zhang, Jie Yang, Yingxin Zhang
  • Patent number: 9539311
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: January 10, 2017
    Assignees: Novozymes A/S, Novozymes Inc.
    Inventors: Allan Svendsen, Michael Skjoet, Debbie Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Patent number: 9513289
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: December 6, 2016
    Assignees: The United Sates of America, as Represented by the Department of Veterans Affairs, University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • Patent number: 9447392
    Abstract: The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 20, 2016
    Assignee: Novozymes A/S
    Inventors: Steffen Danielsen, Lars Kobberoee Skov, Ricardo Leite, Vincent Laize, M. Leonor Cancela Da Fonseca
  • Patent number: 9415122
    Abstract: A molecular probe for use in detecting, monitoring, and/or imaging cancer cells and/or cancer cell metastasis, migration, dispersal, and/or invasion includes a targeting agent and a detectable moiety. The targeting agent specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: August 16, 2016
    Assignee: Case Western Reserve University
    Inventor: Susann Brady-Kalnay
  • Patent number: 9415092
    Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: August 16, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Wenchao Yang
  • Patent number: 9384543
    Abstract: A method of characterizing a person's skin imperfections uses a digital color image-taking device to take at least one digital image of an area of skin including at least one imperfection to be characterized. An apparatus for characterizing the imperfections of the skin and a method for measuring the effectiveness of a treatment for skin imperfections use an active cosmetic, dermatological or pharmaceutical agent and further measure the effectiveness of a staining method aiming to attenuate or mask skin imperfections.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: July 5, 2016
    Assignee: LVMH RECHERCHE
    Inventors: Sandrine Stephan, Delphine Pelle de Queral
  • Patent number: 9365840
    Abstract: The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium Buttiauxella, and which comprises at least one of the following amino acids at the position indicated: 119N, 120L, and/or 121E. These phytases have an improved specific activity. Additional specific amino acid substitutions are also disclosed which characterize and distinguish additional phytases of the invention having improved properties such as temperature and/or pH stability, pH activity profile, temperature activity profile, substrate profile, improved performance in animal feed in vitro or in vivo. The invention also relates to isolated polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 14, 2016
    Assignee: Novozymes A/S
    Inventors: Carsten Sjoeholm, Soeren Flensted Lassen, Lars Kobberoee Skov, Leonardo De Maria
  • Patent number: 9315861
    Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: April 19, 2016
    Assignee: Life Technologies Corporation
    Inventors: Stephen Hendricks, David King, Lei Xi, Marian Peris
  • Patent number: 9309503
    Abstract: The present invention relates to a recombinant E. coli strain characterized in that the organisms contains a gene coding for a protein having esterase activity. Such E. coli is suitable for the preparation of a protein with esterase activity, whereby the expression takes place without coexpression of GroEL and/or GroES from a plasmid. The expression of glutathione reductase and/or thioredoxin reductase may be abolished by mutation. Furthermore, the ability of the organism to grow under oxygen-rich conditions has been restored by mutation. The expression of the gene of the protein with esterase activity is unaccompanied by the expression of an additional gene encoding a heat shock chaperone protein.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: April 12, 2016
    Assignee: DPx Holdings B.V.
    Inventors: Martin Kietzmann, Helmut Schwab, Harald Pichler, Mirela Ivancic, Oliver May, Rudolf Gijsbertus Marie Luiten
  • Patent number: 9206402
    Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: December 8, 2015
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Patent number: 9206403
    Abstract: A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, and A199S/F227A/S287G/A328W/E441D all have enhanced catalytic efficiency for (?)-cocaine compared with wild-type BChE.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: December 8, 2015
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Hoon Cho, Hsin-Hsiung Tai
  • Patent number: 9200298
    Abstract: The invention provides for a method of producing an isoprenyl alkanoate in a genetically modified host cell. In one embodiment, the method comprises culturing a genetically modified host cell which expresses an enzyme capable of catalyzing the esterification of an isoprenol and a straight-chain fatty acid, such as an alcohol acetyltransferase (AAT), wax ester synthase/diacylglycerol acyltransferase (WS/DGAT) or lipase, under a suitable condition so that the isoprenyl alkanoate is produced.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: December 1, 2015
    Assignee: The Regents of the University of California
    Inventors: Taek Soon Lee, Jeffrey L. Fortman, Jay D. Keasling
  • Patent number: 9163223
    Abstract: The invention relates to a polypeptide comprising the amino acid sequence set out in SEQ ID NO: 2 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1, or a variant polypeptide or variant polynucleotide thereof, wherein the variant polypeptide has at least 82% sequence identity with the sequence set out in SEQ ID NO: 2 or the variant polynucleotide encodes a polypeptide that has at least 82% sequence identity with the sequence set out in SEQ ID NO: 2. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional polypeptide and functional equivalents of the gene or the amino acid sequence. The invention also relates to methods for using the polypeptide in industrial processes. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: October 20, 2015
    Assignee: DSM IP ASSETS B.V.
    Inventors: Margot Elisabeth Francoise Schoonneveld-Bergmans, Wilbert Herman Marie Heijne, Alrik Pieter Los